



Sen. Melinda Bush

**Filed: 1/8/2021**

10100HB2488sam003

LRB101 07727 BMS 74688 a

1 AMENDMENT TO HOUSE BILL 2488

2 AMENDMENT NO. \_\_\_\_\_. Amend House Bill 2488 by replacing  
3 everything after the enacting clause with the following:

4 "Section 5. The Illinois Controlled Substances Act is  
5 amended by changing Section 102 and by adding Section 220 as  
6 follows:

7 (720 ILCS 570/102) (from Ch. 56 1/2, par. 1102)

8 Sec. 102. Definitions. As used in this Act, unless the  
9 context otherwise requires:

10 (a) "Addict" means any person who habitually uses any drug,  
11 chemical, substance or dangerous drug other than alcohol so as  
12 to endanger the public morals, health, safety or welfare or who  
13 is so far addicted to the use of a dangerous drug or controlled  
14 substance other than alcohol as to have lost the power of self  
15 control with reference to his or her addiction.

16 (b) "Administer" means the direct application of a

1 controlled substance, whether by injection, inhalation,  
2 ingestion, or any other means, to the body of a patient,  
3 research subject, or animal (as defined by the Humane  
4 Euthanasia in Animal Shelters Act) by:

5 (1) a practitioner (or, in his or her presence, by his  
6 or her authorized agent),

7 (2) the patient or research subject pursuant to an  
8 order, or

9 (3) a euthanasia technician as defined by the Humane  
10 Euthanasia in Animal Shelters Act.

11 (c) "Agent" means an authorized person who acts on behalf  
12 of or at the direction of a manufacturer, distributor,  
13 dispenser, prescriber, or practitioner. It does not include a  
14 common or contract carrier, public warehouseman or employee of  
15 the carrier or warehouseman.

16 (c-1) "Anabolic Steroids" means any drug or hormonal  
17 substance, chemically and pharmacologically related to  
18 testosterone (other than estrogens, progestins,  
19 corticosteroids, and dehydroepiandrosterone), and includes:

20 (i) 3[beta],17-dihydroxy-5a-androstane,

21 (ii) 3[alpha],17[beta]-dihydroxy-5a-androstane,

22 (iii) 5[alpha]-androstane-3,17-dione,

23 (iv) 1-androstenediol (3[beta],

24 17[beta]-dihydroxy-5[alpha]-androst-1-ene),

25 (v) 1-androstenediol (3[alpha],

26 17[beta]-dihydroxy-5[alpha]-androst-1-ene),

- 1 (vi) 4-androstenediol  
2 (3[beta],17[beta]-dihydroxy-androst-4-ene),  
3 (vii) 5-androstenediol  
4 (3[beta],17[beta]-dihydroxy-androst-5-ene),  
5 (viii) 1-androstenedione  
6 ([5alpha]-androst-1-en-3,17-dione),  
7 (ix) 4-androstenedione  
8 (androst-4-en-3,17-dione),  
9 (x) 5-androstenedione  
10 (androst-5-en-3,17-dione),  
11 (xi) bolasterone (7[alpha],17a-dimethyl-17[beta]-  
12 hydroxyandrost-4-en-3-one),  
13 (xii) boldenone (17[beta]-hydroxyandrost-  
14 1,4,-diene-3-one),  
15 (xiii) boldione (androsta-1,4-  
16 diene-3,17-dione),  
17 (xiv) calusterone (7[beta],17[alpha]-dimethyl-17  
18 [beta]-hydroxyandrost-4-en-3-one),  
19 (xv) clostebol (4-chloro-17[beta]-  
20 hydroxyandrost-4-en-3-one),  
21 (xvi) dehydrochloromethyltestosterone (4-chloro-  
22 17[beta]-hydroxy-17[alpha]-methyl-  
23 androst-1,4-dien-3-one),  
24 (xvii) desoxymethyltestosterone  
25 (17[alpha]-methyl-5[alpha]  
26 -androst-2-en-17[beta]-ol) (a.k.a., madol),

1 (xviii) [ $\delta$ ]1-dihydrotestosterone (a.k.a.  
2 '1-testosterone') (17[ $\beta$ ]-hydroxy-  
3 5[ $\alpha$ ]-androst-1-en-3-one),  
4 (xix) 4-dihydrotestosterone (17[ $\beta$ ]-hydroxy-  
5 androstan-3-one),  
6 (xx) drostanolone (17[ $\beta$ ]-hydroxy-2[ $\alpha$ ]-methyl-  
7 5[ $\alpha$ ]-androstan-3-one),  
8 (xxi) ethylestrenol (17[ $\alpha$ ]-ethyl-17[ $\beta$ ]-  
9 hydroxyestr-4-ene),  
10 (xxii) fluoxymesterone (9-fluoro-17[ $\alpha$ ]-methyl-  
11 1[ $\beta$ ],17[ $\beta$ ]-dihydroxyandrost-4-en-3-one),  
12 (xxiii) formebolone (2-formyl-17[ $\alpha$ ]-methyl-11[ $\alpha$ ],  
13 17[ $\beta$ ]-dihydroxyandrost-1,4-dien-3-one),  
14 (xxiv) furazabol (17[ $\alpha$ ]-methyl-17[ $\beta$ ]-  
15 hydroxyandrostan[2,3-c]-furan),  
16 (xxv) 13[ $\beta$ ]-ethyl-17[ $\beta$ ]-hydroxygon-4-en-3-one,  
17 (xxvi) 4-hydroxytestosterone (4,17[ $\beta$ ]-dihydroxy-  
18 androst-4-en-3-one),  
19 (xxvii) 4-hydroxy-19-nortestosterone (4,17[ $\beta$ ]-  
20 dihydroxy-estr-4-en-3-one),  
21 (xxviii) mestanolone (17[ $\alpha$ ]-methyl-17[ $\beta$ ]-  
22 hydroxy-5-androstan-3-one),  
23 (xxix) mesterolone (1-methyl-17[ $\beta$ ]-hydroxy-  
24 [5 $\alpha$ ]-androstan-3-one),  
25 (xxx) methandienone (17[ $\alpha$ ]-methyl-17[ $\beta$ ]-  
26 hydroxyandrost-1,4-dien-3-one),

- 1 (xxxi) methandriol (17[alpha]-methyl-3[beta],17[beta]-  
2 dihydroxyandrost-5-ene),  
3 (xxxii) methenolone (1-methyl-17[beta]-hydroxy-  
4 5[alpha]-androst-1-en-3-one),  
5 (xxxiii) 17[alpha]-methyl-3[beta], 17[beta]-  
6 dihydroxy-5a-androstane,  
7 (xxxiv) 17[alpha]-methyl-3[alpha],17[beta]-dihydroxy  
8 -5a-androstane,  
9 (xxxv) 17[alpha]-methyl-3[beta],17[beta]-  
10 dihydroxyandrost-4-ene),  
11 (xxxvi) 17[alpha]-methyl-4-hydroxynandrolone (17[alpha]-  
12 methyl-4-hydroxy-17[beta]-hydroxyestr-4-en-3-one),  
13 (xxxvii) methyldienolone (17[alpha]-methyl-17[beta]-  
14 hydroxyestra-4,9(10)-dien-3-one),  
15 (xxxviii) methyltrienolone (17[alpha]-methyl-17[beta]-  
16 hydroxyestra-4,9-11-trien-3-one),  
17 (xxxix) methyltestosterone (17[alpha]-methyl-17[beta]-  
18 hydroxyandrost-4-en-3-one),  
19 (xl) mibolerone (7[alpha],17a-dimethyl-17[beta]-  
20 hydroxyestr-4-en-3-one),  
21 (xli) 17[alpha]-methyl-[delta]1-dihydrotestosterone  
22 (17b[beta]-hydroxy-17[alpha]-methyl-5[alpha]-  
23 androst-1-en-3-one) (a.k.a. '17-[alpha]-methyl-  
24 1-testosterone'),  
25 (xlii) nandrolone (17[beta]-hydroxyestr-4-en-3-one),  
26 (xliii) 19-nor-4-androstenediol (3[beta], 17[beta]-

1 dihydroxyestr-4-ene),  
2 (xliv) 19-nor-4-androstenediol (3[alpha], 17[beta]-  
3 dihydroxyestr-4-ene),  
4 (xlv) 19-nor-5-androstenediol (3[beta], 17[beta]-  
5 dihydroxyestr-5-ene),  
6 (xlvi) 19-nor-5-androstenediol (3[alpha], 17[beta]-  
7 dihydroxyestr-5-ene),  
8 (xlvii) 19-nor-4,9(10)-androstadienedione  
9 (estra-4,9(10)-diene-3,17-dione),  
10 (xlviii) 19-nor-4-androstenedione (estr-4-  
11 en-3,17-dione),  
12 (xlix) 19-nor-5-androstenedione (estr-5-  
13 en-3,17-dione),  
14 (l) norbolethone (13[beta], 17a-diethyl-17[beta]-  
15 hydroxygon-4-en-3-one),  
16 (li) norclostebol (4-chloro-17[beta]-  
17 hydroxyestr-4-en-3-one),  
18 (lii) norethandrolone (17[alpha]-ethyl-17[beta]-  
19 hydroxyestr-4-en-3-one),  
20 (liii) normethandrolone (17[alpha]-methyl-17[beta]-  
21 hydroxyestr-4-en-3-one),  
22 (liv) oxandrolone (17[alpha]-methyl-17[beta]-hydroxy-  
23 2-oxa-5[alpha]-androstan-3-one),  
24 (lv) oxymesterone (17[alpha]-methyl-4,17[beta]-  
25 dihydroxyandrost-4-en-3-one),  
26 (lvi) oxymetholone (17[alpha]-methyl-2-hydroxymethylene-

- 1           17[beta]-hydroxy-(5[alpha]-androstan-3-one),  
2           (lvii) stanozolol (17[alpha]-methyl-17[beta]-hydroxy-  
3           (5[alpha]-androst-2-eno[3,2-c]-pyrazole),  
4           (lviii) stenbolone (17[beta]-hydroxy-2-methyl-  
5           (5[alpha]-androst-1-en-3-one),  
6           (lix) testolactone (13-hydroxy-3-oxo-13,17-  
7           secoandrosta-1,4-dien-17-oic  
8           acid lactone),  
9           (lx) testosterone (17[beta]-hydroxyandrost-  
10           4-en-3-one),  
11           (lxi) tetrahydrogestrinone (13[beta], 17[alpha]-  
12           diethyl-17[beta]-hydroxygon-  
13           4,9,11-trien-3-one),  
14           (lxii) trenbolone (17[beta]-hydroxyestr-4,9,  
15           11-trien-3-one).

16           Any person who is otherwise lawfully in possession of an  
17           anabolic steroid, or who otherwise lawfully manufactures,  
18           distributes, dispenses, delivers, or possesses with intent to  
19           deliver an anabolic steroid, which anabolic steroid is  
20           expressly intended for and lawfully allowed to be administered  
21           through implants to livestock or other nonhuman species, and  
22           which is approved by the Secretary of Health and Human Services  
23           for such administration, and which the person intends to  
24           administer or have administered through such implants, shall  
25           not be considered to be in unauthorized possession or to  
26           unlawfully manufacture, distribute, dispense, deliver, or

1 possess with intent to deliver such anabolic steroid for  
2 purposes of this Act.

3 (d) "Administration" means the Drug Enforcement  
4 Administration, United States Department of Justice, or its  
5 successor agency.

6 (d-5) "Clinical Director, Prescription Monitoring Program"  
7 means a Department of Human Services administrative employee  
8 licensed to either prescribe or dispense controlled substances  
9 who shall run the clinical aspects of the Department of Human  
10 Services Prescription Monitoring Program and its Prescription  
11 Information Library.

12 (d-10) "Compounding" means the preparation and mixing of  
13 components, excluding flavorings, (1) as the result of a  
14 prescriber's prescription drug order or initiative based on the  
15 prescriber-patient-pharmacist relationship in the course of  
16 professional practice or (2) for the purpose of, or incident  
17 to, research, teaching, or chemical analysis and not for sale  
18 or dispensing. "Compounding" includes the preparation of drugs  
19 or devices in anticipation of receiving prescription drug  
20 orders based on routine, regularly observed dispensing  
21 patterns. Commercially available products may be compounded  
22 for dispensing to individual patients only if both of the  
23 following conditions are met: (i) the commercial product is not  
24 reasonably available from normal distribution channels in a  
25 timely manner to meet the patient's needs and (ii) the  
26 prescribing practitioner has requested that the drug be



1 compounded.

2 (e) "Control" means to add a drug or other substance, or  
3 immediate precursor, to a Schedule whether by transfer from  
4 another Schedule or otherwise.

5 (f) "Controlled Substance" means (i) a drug, substance,  
6 immediate precursor, or synthetic drug in the Schedules of  
7 Article II of this Act or (ii) a drug or other substance, or  
8 immediate precursor, designated as a controlled substance by  
9 the Department through administrative rule. The term does not  
10 include distilled spirits, wine, malt beverages, or tobacco, as  
11 those terms are defined or used in the Liquor Control Act of  
12 1934 and the Tobacco Products Tax Act of 1995.

13 (f-5) "Controlled substance analog" means a substance:

14 (1) the chemical structure of which is substantially  
15 similar to the chemical structure of a controlled substance  
16 in Schedule I or II;

17 (2) which has a stimulant, depressant, or  
18 hallucinogenic effect on the central nervous system that is  
19 substantially similar to or greater than the stimulant,  
20 depressant, or hallucinogenic effect on the central  
21 nervous system of a controlled substance in Schedule I or  
22 II; or

23 (3) with respect to a particular person, which such  
24 person represents or intends to have a stimulant,  
25 depressant, or hallucinogenic effect on the central  
26 nervous system that is substantially similar to or greater

1 than the stimulant, depressant, or hallucinogenic effect  
2 on the central nervous system of a controlled substance in  
3 Schedule I or II.

4 (g) "Counterfeit substance" means a controlled substance,  
5 which, or the container or labeling of which, without  
6 authorization bears the trademark, trade name, or other  
7 identifying mark, imprint, number or device, or any likeness  
8 thereof, of a manufacturer, distributor, or dispenser other  
9 than the person who in fact manufactured, distributed, or  
10 dispensed the substance.

11 (h) "Deliver" or "delivery" means the actual, constructive  
12 or attempted transfer of possession of a controlled substance,  
13 with or without consideration, whether or not there is an  
14 agency relationship.

15 (i) "Department" means the Illinois Department of Human  
16 Services (as successor to the Department of Alcoholism and  
17 Substance Abuse) or its successor agency.

18 (j) (Blank).

19 (k) "Department of Corrections" means the Department of  
20 Corrections of the State of Illinois or its successor agency.

21 (l) "Department of Financial and Professional Regulation"  
22 means the Department of Financial and Professional Regulation  
23 of the State of Illinois or its successor agency.

24 (m) "Depressant" means any drug that (i) causes an overall  
25 depression of central nervous system functions, (ii) causes  
26 impaired consciousness and awareness, and (iii) can be

1 habit-forming or lead to a substance abuse problem, including  
2 but not limited to alcohol, cannabis and its active principles  
3 and their analogs, benzodiazepines and their analogs,  
4 barbiturates and their analogs, opioids (natural and  
5 synthetic) and their analogs, and chloral hydrate and similar  
6 sedative hypnotics.

7 (n) (Blank).

8 (o) "Director" means the Director of the Illinois State  
9 Police or his or her designated agents.

10 (p) "Dispense" means to deliver a controlled substance to  
11 an ultimate user or research subject by or pursuant to the  
12 lawful order of a prescriber, including the prescribing,  
13 administering, packaging, labeling, or compounding necessary  
14 to prepare the substance for that delivery.

15 (q) "Dispenser" means a practitioner who dispenses.

16 (r) "Distribute" means to deliver, other than by  
17 administering or dispensing, a controlled substance.

18 (s) "Distributor" means a person who distributes.

19 (t) "Drug" means (1) substances recognized as drugs in the  
20 official United States Pharmacopoeia, Official Homeopathic  
21 Pharmacopoeia of the United States, or official National  
22 Formulary, or any supplement to any of them; (2) substances  
23 intended for use in diagnosis, cure, mitigation, treatment, or  
24 prevention of disease in man or animals; (3) substances (other  
25 than food) intended to affect the structure of any function of  
26 the body of man or animals and (4) substances intended for use

1 as a component of any article specified in clause (1), (2), or  
2 (3) of this subsection. It does not include devices or their  
3 components, parts, or accessories.

4 (t-3) "Electronic health record" or "EHR" means an  
5 electronic record of health-related information on an  
6 individual that is created, gathered, managed, and consulted by  
7 authorized health care clinicians and staff.

8 (t-3.5) "Electronic health record system" or "EHR system"  
9 means any computer-based system or combination of federally  
10 certified Health IT Modules (defined at 42 CFR 170.102 or its  
11 successor) used as a repository for electronic health records  
12 and accessed or updated by a prescriber or authorized surrogate  
13 in the ordinary course of his or her medical practice. For  
14 purposes of connecting to the Prescription Information Library  
15 maintained by the Bureau of Pharmacy and Clinical Support  
16 Systems or its successor, an EHR system may connect to the  
17 Prescription Information Library directly or through all or  
18 part of a computer program or system that is a federally  
19 certified Health IT Module maintained by a third party and used  
20 by the EHR system to secure access to the database.

21 (t-4) "Emergency medical services personnel" has the  
22 meaning ascribed to it in the Emergency Medical Services (EMS)  
23 Systems Act.

24 (t-5) "Euthanasia agency" means an entity certified by the  
25 Department of Financial and Professional Regulation for the  
26 purpose of animal euthanasia that holds an animal control

1 facility license or animal shelter license under the Animal  
2 Welfare Act. A euthanasia agency is authorized to purchase,  
3 store, possess, and utilize Schedule II nonnarcotic and  
4 Schedule III nonnarcotic drugs for the sole purpose of animal  
5 euthanasia.

6 (t-10) "Euthanasia drugs" means Schedule II or Schedule III  
7 substances (nonnarcotic controlled substances) that are used  
8 by a euthanasia agency for the purpose of animal euthanasia.

9 (u) "Good faith" means the prescribing or dispensing of a  
10 controlled substance by a practitioner in the regular course of  
11 professional treatment to or for any person who is under his or  
12 her treatment for a pathology or condition other than that  
13 individual's physical or psychological dependence upon or  
14 addiction to a controlled substance, except as provided herein:  
15 and application of the term to a pharmacist shall mean the  
16 dispensing of a controlled substance pursuant to the  
17 prescriber's order which in the professional judgment of the  
18 pharmacist is lawful. The pharmacist shall be guided by  
19 accepted professional standards including, but not limited to  
20 the following, in making the judgment:

21 (1) lack of consistency of prescriber-patient  
22 relationship,

23 (2) frequency of prescriptions for same drug by one  
24 prescriber for large numbers of patients,

25 (3) quantities beyond those normally prescribed,

26 (4) unusual dosages (recognizing that there may be

1 clinical circumstances where more or less than the usual  
2 dose may be used legitimately),

3 (5) unusual geographic distances between patient,  
4 pharmacist and prescriber,

5 (6) consistent prescribing of habit-forming drugs.

6 (u-0.5) "Hallucinogen" means a drug that causes markedly  
7 altered sensory perception leading to hallucinations of any  
8 type.

9 (u-1) "Home infusion services" means services provided by a  
10 pharmacy in compounding solutions for direct administration to  
11 a patient in a private residence, long-term care facility, or  
12 hospice setting by means of parenteral, intravenous,  
13 intramuscular, subcutaneous, or intraspinal infusion.

14 (u-5) "Illinois State Police" means the State Police of the  
15 State of Illinois, or its successor agency.

16 (v) "Immediate precursor" means a substance:

17 (1) which the Department has found to be and by rule  
18 designated as being a principal compound used, or produced  
19 primarily for use, in the manufacture of a controlled  
20 substance;

21 (2) which is an immediate chemical intermediary used or  
22 likely to be used in the manufacture of such controlled  
23 substance; and

24 (3) the control of which is necessary to prevent,  
25 curtail or limit the manufacture of such controlled  
26 substance.

1           (w) "Instructional activities" means the acts of teaching,  
2           educating or instructing by practitioners using controlled  
3           substances within educational facilities approved by the State  
4           Board of Education or its successor agency.

5           (x) "Local authorities" means a duly organized State,  
6           County or Municipal peace unit or police force.

7           (y) "Look-alike substance" means a substance, other than a  
8           controlled substance which (1) by overall dosage unit  
9           appearance, including shape, color, size, markings or lack  
10          thereof, taste, consistency, or any other identifying physical  
11          characteristic of the substance, would lead a reasonable person  
12          to believe that the substance is a controlled substance, or (2)  
13          is expressly or impliedly represented to be a controlled  
14          substance or is distributed under circumstances which would  
15          lead a reasonable person to believe that the substance is a  
16          controlled substance. For the purpose of determining whether  
17          the representations made or the circumstances of the  
18          distribution would lead a reasonable person to believe the  
19          substance to be a controlled substance under this clause (2) of  
20          subsection (y), the court or other authority may consider the  
21          following factors in addition to any other factor that may be  
22          relevant:

23                 (a) statements made by the owner or person in control  
24                 of the substance concerning its nature, use or effect;

25                 (b) statements made to the buyer or recipient that the  
26                 substance may be resold for profit;

1           (c) whether the substance is packaged in a manner  
2 normally used for the illegal distribution of controlled  
3 substances;

4           (d) whether the distribution or attempted distribution  
5 included an exchange of or demand for money or other  
6 property as consideration, and whether the amount of the  
7 consideration was substantially greater than the  
8 reasonable retail market value of the substance.

9           Clause (1) of this subsection (y) shall not apply to a  
10 noncontrolled substance in its finished dosage form that was  
11 initially introduced into commerce prior to the initial  
12 introduction into commerce of a controlled substance in its  
13 finished dosage form which it may substantially resemble.

14           Nothing in this subsection (y) prohibits the dispensing or  
15 distributing of noncontrolled substances by persons authorized  
16 to dispense and distribute controlled substances under this  
17 Act, provided that such action would be deemed to be carried  
18 out in good faith under subsection (u) if the substances  
19 involved were controlled substances.

20           Nothing in this subsection (y) or in this Act prohibits the  
21 manufacture, preparation, propagation, compounding,  
22 processing, packaging, advertising or distribution of a drug or  
23 drugs by any person registered pursuant to Section 510 of the  
24 Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360).

25           (y-1) "Mail-order pharmacy" means a pharmacy that is  
26 located in a state of the United States that delivers,



1 dispenses or distributes, through the United States Postal  
2 Service or other common carrier, to Illinois residents, any  
3 substance which requires a prescription.

4 (z) "Manufacture" means the production, preparation,  
5 propagation, compounding, conversion or processing of a  
6 controlled substance other than methamphetamine, either  
7 directly or indirectly, by extraction from substances of  
8 natural origin, or independently by means of chemical  
9 synthesis, or by a combination of extraction and chemical  
10 synthesis, and includes any packaging or repackaging of the  
11 substance or labeling of its container, except that this term  
12 does not include:

13 (1) by an ultimate user, the preparation or compounding  
14 of a controlled substance for his or her own use; or

15 (2) by a practitioner, or his or her authorized agent  
16 under his or her supervision, the preparation,  
17 compounding, packaging, or labeling of a controlled  
18 substance:

19 (a) as an incident to his or her administering or  
20 dispensing of a controlled substance in the course of  
21 his or her professional practice; or

22 (b) as an incident to lawful research, teaching or  
23 chemical analysis and not for sale.

24 (z-1) (Blank).

25 (z-5) "Medication shopping" means the conduct prohibited  
26 under subsection (a) of Section 314.5 of this Act.

1           (z-10) "Mid-level practitioner" means (i) a physician  
2 assistant who has been delegated authority to prescribe through  
3 a written delegation of authority by a physician licensed to  
4 practice medicine in all of its branches, in accordance with  
5 Section 7.5 of the Physician Assistant Practice Act of 1987,  
6 (ii) an advanced practice registered nurse who has been  
7 delegated authority to prescribe through a written delegation  
8 of authority by a physician licensed to practice medicine in  
9 all of its branches or by a podiatric physician, in accordance  
10 with Section 65-40 of the Nurse Practice Act, (iii) an advanced  
11 practice registered nurse certified as a nurse practitioner,  
12 nurse midwife, or clinical nurse specialist who has been  
13 granted authority to prescribe by a hospital affiliate in  
14 accordance with Section 65-45 of the Nurse Practice Act, (iv)  
15 an animal euthanasia agency, or (v) a prescribing psychologist.

16           (aa) "Narcotic drug" means any of the following, whether  
17 produced directly or indirectly by extraction from substances  
18 of vegetable origin, or independently by means of chemical  
19 synthesis, or by a combination of extraction and chemical  
20 synthesis:

21           (1) opium, opiates, derivatives of opium and opiates,  
22 including their isomers, esters, ethers, salts, and salts  
23 of isomers, esters, and ethers, whenever the existence of  
24 such isomers, esters, ethers, and salts is possible within  
25 the specific chemical designation; however the term  
26 "narcotic drug" does not include the isoquinoline

1 alkaloids of opium;

2 (2) (blank);

3 (3) opium poppy and poppy straw;

4 (4) coca leaves, except coca leaves and extracts of  
5 coca leaves from which substantially all of the cocaine and  
6 ecgonine, and their isomers, derivatives and salts, have  
7 been removed;

8 (5) cocaine, its salts, optical and geometric isomers,  
9 and salts of isomers;

10 (6) ecgonine, its derivatives, their salts, isomers,  
11 and salts of isomers;

12 (7) any compound, mixture, or preparation which  
13 contains any quantity of any of the substances referred to  
14 in subparagraphs (1) through (6).

15 (bb) "Nurse" means a registered nurse licensed under the  
16 Nurse Practice Act.

17 (cc) (Blank).

18 (dd) "Opiate" means any substance having an addiction  
19 forming or addiction sustaining liability similar to morphine  
20 or being capable of conversion into a drug having addiction  
21 forming or addiction sustaining liability.

22 (ee) "Opium poppy" means the plant of the species *Papaver*  
23 *somniferum* L., except its seeds.

24 (ee-5) "Oral dosage" means a tablet, capsule, elixir, or  
25 solution or other liquid form of medication intended for  
26 administration by mouth, but the term does not include a form

1 of medication intended for buccal, sublingual, or transmucosal  
2 administration.

3 (ff) "Parole and Pardon Board" means the Parole and Pardon  
4 Board of the State of Illinois or its successor agency.

5 (gg) "Person" means any individual, corporation,  
6 mail-order pharmacy, government or governmental subdivision or  
7 agency, business trust, estate, trust, partnership or  
8 association, or any other entity.

9 (hh) "Pharmacist" means any person who holds a license or  
10 certificate of registration as a registered pharmacist, a local  
11 registered pharmacist or a registered assistant pharmacist  
12 under the Pharmacy Practice Act.

13 (ii) "Pharmacy" means any store, ship or other place in  
14 which pharmacy is authorized to be practiced under the Pharmacy  
15 Practice Act.

16 (ii-5) "Pharmacy shopping" means the conduct prohibited  
17 under subsection (b) of Section 314.5 of this Act.

18 (ii-10) "Physician" (except when the context otherwise  
19 requires) means a person licensed to practice medicine in all  
20 of its branches.

21 (jj) "Poppy straw" means all parts, except the seeds, of  
22 the opium poppy, after mowing.

23 (kk) "Practitioner" means a physician licensed to practice  
24 medicine in all its branches, dentist, optometrist, podiatric  
25 physician, veterinarian, scientific investigator, pharmacist,  
26 physician assistant, advanced practice registered nurse,

1 licensed practical nurse, registered nurse, emergency medical  
2 services personnel, hospital, laboratory, or pharmacy, or  
3 other person licensed, registered, or otherwise lawfully  
4 permitted by the United States or this State to distribute,  
5 dispense, conduct research with respect to, administer or use  
6 in teaching or chemical analysis, a controlled substance in the  
7 course of professional practice or research.

8 (ll) "Pre-printed prescription" means a written  
9 prescription upon which the designated drug has been indicated  
10 prior to the time of issuance; the term does not mean a written  
11 prescription that is individually generated by machine or  
12 computer in the prescriber's office.

13 (mm) "Prescriber" means a physician licensed to practice  
14 medicine in all its branches, dentist, optometrist,  
15 prescribing psychologist licensed under Section 4.2 of the  
16 Clinical Psychologist Licensing Act with prescriptive  
17 authority delegated under Section 4.3 of the Clinical  
18 Psychologist Licensing Act, podiatric physician, or  
19 veterinarian who issues a prescription, a physician assistant  
20 who issues a prescription for a controlled substance in  
21 accordance with Section 303.05, a written delegation, and a  
22 written collaborative agreement required under Section 7.5 of  
23 the Physician Assistant Practice Act of 1987, an advanced  
24 practice registered nurse with prescriptive authority  
25 delegated under Section 65-40 of the Nurse Practice Act and in  
26 accordance with Section 303.05, a written delegation, and a

1 written collaborative agreement under Section 65-35 of the  
2 Nurse Practice Act, an advanced practice registered nurse  
3 certified as a nurse practitioner, nurse midwife, or clinical  
4 nurse specialist who has been granted authority to prescribe by  
5 a hospital affiliate in accordance with Section 65-45 of the  
6 Nurse Practice Act and in accordance with Section 303.05, or an  
7 advanced practice registered nurse certified as a nurse  
8 practitioner, nurse midwife, or clinical nurse specialist who  
9 has full practice authority pursuant to Section 65-43 of the  
10 Nurse Practice Act.

11 (nn) "Prescription" means a written, facsimile, or oral  
12 order, or an electronic order that complies with applicable  
13 federal requirements, of a physician licensed to practice  
14 medicine in all its branches, dentist, podiatric physician or  
15 veterinarian for any controlled substance, of an optometrist in  
16 accordance with Section 15.1 of the Illinois Optometric  
17 Practice Act of 1987, of a prescribing psychologist licensed  
18 under Section 4.2 of the Clinical Psychologist Licensing Act  
19 with prescriptive authority delegated under Section 4.3 of the  
20 Clinical Psychologist Licensing Act, of a physician assistant  
21 for a controlled substance in accordance with Section 303.05, a  
22 written delegation, and a written collaborative agreement  
23 required under Section 7.5 of the Physician Assistant Practice  
24 Act of 1987, of an advanced practice registered nurse with  
25 prescriptive authority delegated under Section 65-40 of the  
26 Nurse Practice Act who issues a prescription for a controlled

1 substance in accordance with Section 303.05, a written  
2 delegation, and a written collaborative agreement under  
3 Section 65-35 of the Nurse Practice Act, of an advanced  
4 practice registered nurse certified as a nurse practitioner,  
5 nurse midwife, or clinical nurse specialist who has been  
6 granted authority to prescribe by a hospital affiliate in  
7 accordance with Section 65-45 of the Nurse Practice Act and in  
8 accordance with Section 303.05 when required by law, or of an  
9 advanced practice registered nurse certified as a nurse  
10 practitioner, nurse midwife, or clinical nurse specialist who  
11 has full practice authority pursuant to Section 65-43 of the  
12 Nurse Practice Act.

13 (nn-5) "Prescription Information Library" (PIL) means an  
14 electronic library that contains reported controlled substance  
15 data.

16 (nn-10) "Prescription Monitoring Program" (PMP) means the  
17 entity that collects, tracks, and stores reported data on  
18 controlled substances and select drugs pursuant to Section 316.

19 (oo) "Production" or "produce" means manufacture,  
20 planting, cultivating, growing, or harvesting of a controlled  
21 substance other than methamphetamine.

22 (pp) "Registrant" means every person who is required to  
23 register under Section 302 of this Act.

24 (qq) "Registry number" means the number assigned to each  
25 person authorized to handle controlled substances under the  
26 laws of the United States and of this State.

1           (qq-5) "Secretary" means, as the context requires, either  
2 the Secretary of the Department or the Secretary of the  
3 Department of Financial and Professional Regulation, and the  
4 Secretary's designated agents.

5           (rr) "State" includes the State of Illinois and any state,  
6 district, commonwealth, territory, insular possession thereof,  
7 and any area subject to the legal authority of the United  
8 States of America.

9           (rr-5) "Stimulant" means any drug that (i) causes an  
10 overall excitation of central nervous system functions, (ii)  
11 causes impaired consciousness and awareness, and (iii) can be  
12 habit-forming or lead to a substance abuse problem, including  
13 but not limited to amphetamines and their analogs,  
14 methylphenidate and its analogs, cocaine, and phencyclidine  
15 and its analogs.

16           (rr-10) "Synthetic drug" includes, but is not limited to,  
17 any synthetic cannabinoids or piperazines or any synthetic  
18 cathinones as provided for in Schedule I.

19           (ss) "Ultimate user" means a person who lawfully possesses  
20 a controlled substance for his or her own use or for the use of  
21 a member of his or her household or for administering to an  
22 animal owned by him or her or by a member of his or her  
23 household.

24           (Source: P.A. 99-78, eff. 7-20-15; 99-173, eff. 7-29-15;  
25 99-371, eff. 1-1-16; 99-480, eff. 9-9-15; 99-642, eff. 7-28-16;  
26 100-280, eff. 1-1-18; 100-453, eff. 8-25-17; 100-513, eff.



1 1-1-18; 100-789, eff. 1-1-19; 100-863, eff. 8-14-18.)

2 (720 ILCS 570/220 new)

3 Sec. 220. Electronic health record systems. The Bureau of  
4 Pharmacy and Clinical Support Systems shall establish a form to  
5 allow EHR systems to certify the identity of a third party that  
6 will provide access to the Prescription Information Library for  
7 the EHR system using all or part of a computer program or  
8 system that is a federally certified Health IT Module for the  
9 EHR system. Before the Health IT Module is permitted to connect  
10 to the Prescription Information Library, it must enter into a  
11 business associate agreement with the EHR system that requires  
12 the Health IT Module to agree to adhere to all requirements  
13 imposed on the EHR system by the laws of this State, including  
14 data privacy and security obligations that the Bureau otherwise  
15 imposes on EHR systems."